Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
Status:
Completed
Trial end date:
2018-04-24
Target enrollment:
Participant gender:
Summary
This is a study of multiple doses of inhaled QBW276 in patients with cystic fibrosis on top
of standard of care. The study was divided into 3 Cohorts. Cohorts 1 and 2 are designed to be
a randomized, double-blind, placebo-controlled, parallel arm, multiple dose study to assess
the safety, tolerability, pharmacokinetics, and preliminary efficacy of inhaled QBW276 over 1
week (cohort 1) or 2 weeks (cohort 2) in patients with cystic fibrosis regardless of their
genotype.
The study was terminated after Cohort 2 due to the resource issues.